ArticleJournal of hematology & oncology2018
Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.
Article in Journal of hematology & oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- A Drug-Gated, Modular STAb-T Immunotherapy With External Control.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Precise control of switchable chimeric antigen receptor T cells allows enhanced safety and less T cell exhaustion.Journal of translational medicine · 2026Article
- Effects of Tumor Microenvironment on Lung Cancer Stem Cells: Bidirectional Regulatory Mechanisms.Cancer medicine · 2026Review
- SubvertingBiology · 2024Review
- Immunopeptides: immunomodulatory strategies and prospects for ocular immunity applications.Frontiers in immunology · 2024Review
- Application of novel CAR technologies to improve treatment of autoimmune disease.Frontiers in immunology · 2024Review
- Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.International journal of molecular sciences · 2023Review
- Challenges of Anti-Mesothelin CAR-T-Cell Therapy.Cancers · 2023Review
- Review
- The predictive role of soluble programmed death ligand 1 in digestive system cancers.Frontiers in oncology · 2023Review
- Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.Frontiers in immunology · 2023Article
- CAR-T cell potency: from structural elements to vector backbone components.Biomarker research · 2022Review
- Next-generation CAR T cells to overcome current drawbacks.International journal of hematology · 2021Review
- Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy.Signal transduction and targeted therapy · 2021Review
- Integrins as attractive targets for cancer therapeutics.Acta pharmaceutica Sinica. B · 2021Review
- Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting.International journal of molecular sciences · 2020Review
- Review
- Recent Advances in Allogeneic CAR-T Cells.Biomolecules · 2020Review
- Mesothelin as a biomarker for targeted therapy.Biomarker research · 2019Review
- Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.Journal of hematology & oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChimeric antigen receptors (CARs) presented on T cell surfaces enable redirection of T cell specificity, which has enormous promise in antitumor therapy. However, excessive activity and poor control over such engineered T cells cause significant safety challenges, such as cytokine release syndrome and organ toxicities. To enhance the specificity and controllable activity of CAR-T cells, we report a novel switchable dual-receptor CAR-engineered T (sdCAR-T) cell and a new switch molecule of FITC-HM-3 bifunctional molecule (FHBM) in this study.
methodsWe designed a fusion molecule comprising FITC and HM-3. HM-3, an antitumor peptide including an Arg-Gly-Asp sequence, can specifically target integrin αvβ3 that is presented on some tumor cells. Moreover, to improve the specificity of CAR-T cells, we also generated the sdCAR-T cell line against cognate tumor cells expressing human mesothelin (MSLN) and integrin αvβ3. Finally, the activity of sdCAR-T cell and FHBM is verified via in vitro and in vivo experiments.
resultsIn the presence of FHBM, the designed sdCAR-T cells exerted high activity including activation and proliferation and had specific cytotoxicity in a time- and dose-dependent manner in vitro. Furthermore, using a combination of FHBM in nude mice, sdCAR-T cells significantly inhibited the growth of MSLN
conclusionsOur data indicate that FHBM can accurately control timing and dose of injected CAR-T cells, and sdCAR-T cells exert significant antitumor activity while releasing lower levels of cytokines for the cognate tumor cells expressing both MSLN and integrin αvβ3. Therefore, combination therapies using sdCAR-T cells and the switch molecule FHBM have significant potential to treat malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.